Abstract
Dostarlimab is a humanized programmed death 1 (PD-1) receptor monoclonal antibody that blocks interaction with the ligands PD-L1 and PD-L2. GARNET is a phase I study assessing antitumor activity and safety of dostarlimab monotherapy in patients with solid tumors. Here we report TRAEs across cohort A1 (mismatch repair–deficient [dMMR] endometrial cancer [EC]), cohort A2 (mismatch repair–proficient [MMRp] EC), cohort E (non–small cell lung cancer [NSCLC]), and cohort F (dMMR non-EC) of the GARNET trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
